Your browser doesn't support javascript.
loading
Cost-effectiveness of palbociclib plus letrozole versus letrozole alone as a first-line treatment in women with oestrogen receptor-positive, HER2-negative, advanced breast cancer. Revised results for the Swiss health care setting.
Matter-Walstra, K; Schwenkglenks, M; Dedes, K J.
  • Matter-Walstra K; University Basel, Basel, Switzerland. klazien.matter@unibas.ch.
  • Schwenkglenks M; Swiss Group of Clinical Cancer Research (SAKK) Coordinating Centre, Bern, Switzerland. klazien.matter@unibas.ch.
  • Dedes KJ; University Basel, Basel, Switzerland.
Breast Cancer Res Treat ; 163(3): 635, 2017 06.
Article en En | MEDLINE | ID: mdl-28321586

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptores de Estrógenos Tipo de estudio: Evaluation_studies / Health_economic_evaluation Límite: Female / Humans Idioma: En Año: 2017 Tipo del documento: Article

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Receptores de Estrógenos Tipo de estudio: Evaluation_studies / Health_economic_evaluation Límite: Female / Humans Idioma: En Año: 2017 Tipo del documento: Article